Caption Management, LLC Arbutus Biopharma Corp Call Options Transaction History

Caption Management, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.26 - $2.92 $372,899 - $481,800	-165,000 Reduced 82.5%	35,000 $90,000
Q3 2023 Nov 14, 2023	BUY	$1.9 - $2.27 $95,000 - $113,500	50,000 Added 33.33%	200,000 $405,000
Q1 2023 May 15, 2023	BUY	$2.23 - $3.1 $109,047 - $151,590	48,900 Added 48.37%	150,000 $454,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $2,101 - $3,135	1,100 Added 1.1%	101,100 $235,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $188,000 - $288,000	-100,000 Reduced 50.0%	100,000 $192,000

Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $396,000 - $634,000	-200,000 Reduced 50.0%	200,000 $542,000
Q1 2022 May 13, 2022	BUY	$2.42 - $3.98 $544,500 - $895,500	225,000 Added 128.57%	400,000 $1.19 Million
Q4 2021 Feb 11, 2022	BUY	$3.11 - $4.61 $373,200 - $553,200	120,000 Added 218.18%	175,000 $682,000
Q3 2021 Nov 12, 2021	SELL	$2.65 - $4.62 $119,250 - $207,900	-45,000 Reduced 45.0%	55,000 $236,000
Q2 2021 Aug 16, 2021	BUY	$2.5 - $3.51 $250,000 - $351,000	100,000 New	100,000 $303,000
Q1 2019 May 14, 2019	SELL	$3.41 - $4.57 $102,300 - $137,100	-30,000 Closed	0 $0
Q4 2018 Jan 30, 2019	BUY	$3.5 - $9.66 $105,000 - $289,800	30,000 New	30,000 $115,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.